KRAS and non-small cell lung carcinoma: Glycine‐to‐cysteine (G12C) mutation is a dominant KRAS mutation accounting for nearly 44% of KRAS mutations in NSCLC patients, which has been found to be extremely common in NSCLC patients with smoking history.7